Why Participate in our trials?
Clinical trials study whether or not new medicines, devices, or diagnostic techniques work and are safe for use. Patients choose to participate in clinical trials for a variety of reasons such as a desire to contribute to the greater good through science or access to cutting edge treatments. By participating in clinical trials they are frequently seen by highly trained experts in their field. Compensation for time and effort is sometimes offered for trial participation.
Clinical trials are carefully planned and meticulously reviewed by groups of health specialists called Institutional Review Boards. Patients participate exclusively as volunteers for studies and enroll only after a detailed informed consent process. Patient volunteers have the right to drop out of a trial at any time.
CURRENTLY ENROLLING
COPD
Idiopathic Pulmonary Fibrosis
Asthma
Bronchiectasis
For more information on trials or to ask questions contact us here.
COPD
Genentech GB43311
Research Trial
A Phase 2b study to evaluate the efficacy, safety, and pharmacokinetics of Astegolimab compared to placebo in patients with COPD who are former or current smokers and have a history of frequent exacerbations. Subjects will receive subcutaneous injections every 2 weeks thru week 52. Subjects must have 2 or more exacerbations within a 24-month period of time.
COPD
Chiesi Farmaceutici CLI-05593AA3-06
Research Trial
A Phase 3, 52-week, multinational, multicenter, randomized, double-blind, 2-arm parallel group study comparing efficacy, safety and tolerability of the fixed dose triple combination of beclomethasone dipropionate, formoterol fumarate plus glycopyrronium bromide (CHF 5993) with the fixed dose dual combination of beclomethasone dipropionate plus formoterol fumarate (CHF 1535), both administered via pMDI in subjects with COPD. Both inhalers are already approved in the EU as Trimbow® and Foster®. At least 2934 subjects will be enrolled in this study. Subjects should have at least 1 or 2 exacerbations a year. Subjects are required to be on stable maintenance therapy of any combination for COPD.
COPD
Astrazeneca D9180C00012
Research Trial
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA). Patients meeting eligibility criteria will be randomized with Tozorakimab 300mg every 2 weeks add-on therapy vs. placebo in a 3:2 ratio for 52 weeks. Subjects must be on stable dual or triple-maintenance therapy and have had COPD exacerbations in the last year.
Idiopathic Pulmonary Fibrosis
Pliant 74809-IPF-206
Research Trial
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON). Patients meeting eligibility criteria for the study will be randomized 1:1:1 to Bexotegrast 160mg or 320mg vs. placebo for 52 weeks. Standard of care (SOC) background therapy for ILD with nintedanib or pirfenidone is allowed.
Idiopathic Pulmonary Fibrosis
United Therapeutics
Research Trial
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety fo Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis over a 52 week period. Subjects will be randomly assigned 1:1 to inhaled treprostinil or placebo at Baseline. All subjects will initiate inhaled treprostinil (6 mcg/breath) or placebo at a dose of 3 breaths (18 mcg) administered QID (during waking hours) and will titrate to a target dosing regimen for 12 breaths (72 mcg) QID. Standard of care (SOC) background therapy for IPF with either nintedanib or pirfenidone will be allowed.
Idiopathic Pulmonary Fibrosis
BMS IMO271068
Research Trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis. Patients meeting eligibility criteria for the study will be randomized with 60mg or 120mg PO BID in a 1:1:1 ratio or matching placebo for a 52 weeks. Standard of care (SOC) background therapy for ILD with nintedanib or perfindone is allowed.
.
Idiopathic Pulmonary Fibrosis
Tvardi TVD-101-003P
Research Trial
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TTI-101 in Patients with IPF. Patients meeting eligility criteria for the study will be randomized with a 1:1:1:1 to receive 1 of 3 dose levels of TTI-101 or matching placebo for a 12-week treatment period. Standard of care (SOC) background therapy for IPF with nintedanib will be allowed.
Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim 1462-0004
Research Trial
A randomized, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF). Patients meeting eligibility criteria will be randomized with placebo or 0.3mg weekly or 0.1mg daily or 0.6mg daily in a 2:1:1:1 ratio for at least 24 weeks. Standard of Care (SOC) background therapy for IPF with nintedanib or pirfenidone is allowed.
Idiopathic Pulmonary Fibrosis
Daewoong DW_DWN12088201
Research Trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of DWN12088 in Patients with Idiopathic Pulmonary Fibrosis with or without standard-of-care. Patients meeting the eligibility criteria for the study will be randomized with a 2:1 ratio to DWN12088 150 mg BID or the matching placebo. Treatment will be administered orally in fasted state or at least 2 hours after the last meal, for 24 weeks.
.
We are not currently enrolling for Bronchiectasis trials, but we are constantly reviewing new studies for future enrollment.
If you are interested in participating in a study or would like more information, register now or contact The Lung Research Center at 314-439-LUNG (5864) or email: thelungcenter@stlukes-stl.com.
Interstitial Lung Disease
United Therapeutics RIN-PF-305
Research Trial
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Progressive Pulmonary Fibrosis (TETON-PPF). Patients meeting eligibility criteria for the study will be randomized 1:1 to inhaled Treprostinil or placebo for 52 weeks. All subjects will initiate inhaled treprostinil (6 mcg/breath) or placebo at a dose of 3 breaths (18 mcg) administered QID (during waking hours) and will titrate to a target dosing regimen for 12 breaths (72 mcg) QID. Standard of care (SOC) background therapy for ILD with nintedanib or perfindone is allowed.
Interstitial Lung Disease
BMS IM0271015
Research Trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis. Patients meeting eligibility criteria for the study will be randomized with 60mg or 120mg PO BID in a 1:1:1 ratio or matching placebo for a 52 weeks. Standard of care (SOC) background therapy for ILD with nintedanib or perfindone is allowed. BMS-986278 is potent small molecule lysophosphatidic acid receptor 1 antagonist
We are not currently enrolling for Bronchiectasis trials, but we are constantly reviewing new studies for future enrollment.
If you are interested in participating in a study or would like more information, register now or contact The Lung Research Center at 314-439-LUNG (5864) or email: thelungcenter@stlukes-stl.com.
We are not currently enrolling for PE/DVT trials, but we are constantly reviewing new studies for future enrollment.
If you are interested in participating in a study or would like more information, register now or contact The Lung Research Center at 314-439-LUNG (5864) or email: thelungcenter@stlukes-stl.com.
We are not currently enrolling for Pulmonary Hypertension trials, but we are constantly reviewing new studies for future enrollment.
If you are interested in participating in a study or would like more information, register now or contact The Lung Research Center at 314-439-LUNG (5864) or email: thelungcenter@stlukes-stl.com.